BioWorld Asia

May 25, 2011

View Archived Issues

Membrane Receptors Will Open Door to Drug Discovery

EMA Follows FDA Line on Huntexil Development Path

Oxford Biomedica's Parkinson's Drug Improves Motor Function

Spinnovator Raises $56M for New German Start-ups

Going Global: Takeda Paying $13.7B Cash for Nycomed

Shire Acquires Advanced BioHealing for $750M

Other News To Note

GenKyoTex's $20.4M Series C Funds NOX Inhibitor Progress

LONDON – GenKyoTex SA raised CHF18 million (US$20.4 million) in a Series C round, enabling it to take the lead product to the point where it is ready to deliver proof of concept for the company's NOX enzyme inhibition technology. (BioWorld International) Read More

Evotec Shares Fall with Terminated Roche Alliance

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld Science

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...